Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Wei Guo
CONTACT
Xiaodan Lyu
CONTACT
Lead
Nanjing Sanhome Pharmaceutical, Co., Ltd.
This is a phase I, sequential dose escalation followed by cohort expansion study of SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory indolent B-cell hematologic malignancies.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
